JP2021513368A5 - - Google Patents
Info
- Publication number
- JP2021513368A5 JP2021513368A5 JP2020565255A JP2020565255A JP2021513368A5 JP 2021513368 A5 JP2021513368 A5 JP 2021513368A5 JP 2020565255 A JP2020565255 A JP 2020565255A JP 2020565255 A JP2020565255 A JP 2020565255A JP 2021513368 A5 JP2021513368 A5 JP 2021513368A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- variable region
- chain variable
- light chain
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023200834A JP7755635B2 (ja) | 2018-02-13 | 2023-11-28 | 抗ｈｅｒ２抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201801219VA SG10201801219VA (en) | 2018-02-13 | 2018-02-13 | Anti-HER2 Antibodies |
| SG10201801219V | 2018-02-13 | ||
| PCT/SG2019/050077 WO2019160501A1 (en) | 2018-02-13 | 2019-02-12 | Anti-her2 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023200834A Division JP7755635B2 (ja) | 2018-02-13 | 2023-11-28 | 抗ｈｅｒ２抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021513368A JP2021513368A (ja) | 2021-05-27 |
| JP2021513368A5 true JP2021513368A5 (https=) | 2022-02-22 |
| JP7460551B2 JP7460551B2 (ja) | 2024-04-02 |
Family
ID=67621044
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020565255A Active JP7460551B2 (ja) | 2018-02-13 | 2019-02-12 | 抗ｈｅｒ２抗体 |
| JP2023200834A Active JP7755635B2 (ja) | 2018-02-13 | 2023-11-28 | 抗ｈｅｒ２抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023200834A Active JP7755635B2 (ja) | 2018-02-13 | 2023-11-28 | 抗ｈｅｒ２抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11945877B2 (https=) |
| EP (1) | EP3752536A4 (https=) |
| JP (2) | JP7460551B2 (https=) |
| CN (1) | CN112262156B (https=) |
| SG (2) | SG10201801219VA (https=) |
| WO (1) | WO2019160501A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3567049A4 (en) | 2016-12-28 | 2020-08-26 | Green Cross Lab Cell Corporation | CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| KR102774451B1 (ko) | 2017-11-14 | 2025-02-28 | 앱클론(주) | 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체 |
| CN114423787B (zh) | 2019-07-19 | 2025-01-24 | 昂科里斯庞斯公司 | 免疫调节性抗体及其使用方法 |
| EP4153635A4 (en) * | 2020-05-22 | 2024-06-26 | GC Cell Corporation | ANTI-HER2 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND CHIMERIC ANTIGEN RECEPTOR COMPRISING SAME |
| EP3915576A1 (en) * | 2020-05-28 | 2021-12-01 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Chimeric antigen receptors specific for p95her2 and uses thereof |
| CN118574646A (zh) * | 2022-01-19 | 2024-08-30 | 上海优替济生生物医药有限公司 | 环状rna及其用途 |
| WO2023150544A1 (en) * | 2022-02-01 | 2023-08-10 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Simplified method of preparing cells for patient administration |
| US20250222029A1 (en) * | 2022-04-08 | 2025-07-10 | Fate Therapeutics, Inc. | Chimeric antigen receptor for tumor targeting |
| US20250228943A1 (en) | 2022-04-08 | 2025-07-17 | Fate Therapeutics, Inc. | Cells having solid tumor targeting backbone and use thereof |
| CN114805584B (zh) * | 2022-06-30 | 2022-09-09 | 上海优替济生生物医药有限公司 | 抗原结合蛋白及其用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
| KR20060079258A (ko) | 1996-10-18 | 2006-07-05 | 제넨테크, 인크. | 항-ＥｒｂＢ２ 항체 |
| US20090304590A1 (en) * | 2007-05-29 | 2009-12-10 | Wyeth | Therapeutic compositions and methods |
| WO2009055074A2 (en) * | 2007-10-25 | 2009-04-30 | Wyeth | Erbb2 binding proteins and use thereof |
| DK2644194T3 (en) | 2008-03-18 | 2017-07-03 | Genentech Inc | Combinations of an anti-HER2 antibody-drug conjugate and docetaxel |
| WO2009123894A2 (en) | 2008-04-02 | 2009-10-08 | Macrogenics, Inc. | Her2/neu-specific antibodies and methods of using same |
| US20150366955A9 (en) | 2009-11-11 | 2015-12-24 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
| EP2370103B1 (en) | 2008-11-28 | 2016-03-23 | Novartis AG | Pharmaceutical combinations comprising an isoxazole derived hsp90-inhibitor and the her2 inhibitor trastuzumab |
| CN102167742B (zh) | 2010-02-25 | 2014-05-14 | 上海百迈博制药有限公司 | 一种全人源抗her2单克隆抗体、其制备方法及用途 |
| SG11201608192SA (en) | 2014-04-11 | 2016-10-28 | Medimmune Llc | Bispecific her2 antibodies |
| US9975960B2 (en) * | 2014-05-09 | 2018-05-22 | Samsung Electronics Co., Ltd. | Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same |
| CN106661099A (zh) | 2014-05-27 | 2017-05-10 | 中央研究院 | 抗her2醣抗体及其用途 |
| TWI695011B (zh) | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗ｈｅｒ２表位之單株抗體及其使用之方法 |
| ES2806776T3 (es) * | 2014-06-18 | 2021-02-18 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Células NK-92 que expresan CAR como agentes terapéuticos celulares |
| AU2015277100A1 (en) | 2014-06-20 | 2017-02-02 | Abgenomics International Inc. | HER2 antibody-drug conjugates |
| KR101608301B1 (ko) * | 2014-08-22 | 2016-04-12 | 앱클론(주) | Her2에 특이적으로 결합하는 항체 |
| WO2016135239A1 (en) * | 2015-02-25 | 2016-09-01 | Biotecnol Limited | Fusion protein comprising three binding domains to her2 |
| JP2018510652A (ja) | 2015-03-18 | 2018-04-19 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | Ｈｅｒ２／ｅｒｂｂ２キメラ抗原受容体 |
| KR20180083874A (ko) | 2015-11-04 | 2018-07-23 | 사울 제이. 프라이스맨 | Her2를 표적화하는 키메라 항원 수용체 |
| CN106831987B (zh) * | 2015-12-04 | 2020-01-21 | 浙江大学 | 一种抗人her2抗体及其编码基因和应用 |
| EP3241847A1 (en) * | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Her-2 binding antibodies |
| CA3060573A1 (en) * | 2017-04-21 | 2018-10-25 | Baylor College Of Medicine | Oncolytic virotherapy and immunotherapy |
| CN107488636A (zh) * | 2017-09-30 | 2017-12-19 | 山东兴瑞生物科技有限公司 | 一种携带分子开关的抗her2嵌合抗原受体修饰的免疫细胞及其应用 |
-
2018
- 2018-02-13 SG SG10201801219VA patent/SG10201801219VA/en unknown
-
2019
- 2019-02-12 EP EP19754373.9A patent/EP3752536A4/en active Pending
- 2019-02-12 CN CN201980025704.5A patent/CN112262156B/zh active Active
- 2019-02-12 WO PCT/SG2019/050077 patent/WO2019160501A1/en not_active Ceased
- 2019-02-12 US US16/969,119 patent/US11945877B2/en active Active
- 2019-02-12 JP JP2020565255A patent/JP7460551B2/ja active Active
- 2019-02-12 SG SG11202007735TA patent/SG11202007735TA/en unknown
-
2023
- 2023-11-28 JP JP2023200834A patent/JP7755635B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021513368A5 (https=) | ||
| US11673952B2 (en) | Antibodies specific to delta 1 chain of T cell receptor | |
| CA2866612C (en) | Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof | |
| WO2022078425A1 (zh) | 抗her3抗体和抗her3抗体药物偶联物及其医药用途 | |
| KR20200016899A (ko) | 활성화가능 항-pdl1 항체, 및 이의 이용 방법 | |
| JP2020529863A (ja) | 抗ｒｏｒ１抗体とその作製及び使用方法 | |
| US10792370B2 (en) | Antibody-drug conjugate | |
| JP2017529838A5 (https=) | ||
| HUE031017T2 (en) | Antibody Drug Conjugates | |
| CA2952113A1 (en) | Anti-axl antibodies | |
| TWI879889B (zh) | 用於分子接合或工程化的縱排重複癌症靶向胜肽及其於癌症診療中的用途 | |
| JP2024504390A5 (https=) | ||
| KR20240040090A (ko) | 항-dll3 항체 및 이의 제조 방법, 이의 약물 접합체 및 용도 | |
| CN113509558A (zh) | 四价抗体药物偶联物及其应用 | |
| TW202330040A (zh) | 抗ｈｅｒ２抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| JP2023155262A (ja) | プレクチン１結合抗体およびその使用 | |
| TW202517672A (zh) | 抗ｃｄｈ１７抗體及其用途 | |
| JP7679380B2 (ja) | Ｃｄ２７６に特異的な抗体－薬物コンジュゲートおよびその使用 | |
| WO2015131822A1 (zh) | 抗体-药物偶联物Pertuzumab-MCC-DM1、其与Trastuzumab的组合物及其应用 | |
| JP2025524306A (ja) | Ｉｔｇａ２を標的とする抗体及びそれを含む抗体薬物複合体 | |
| JP6989645B2 (ja) | ＥｒｂＢ３に特異的に結合する抗体、及びその用途 | |
| US20240270865A1 (en) | Cancer treatment methods using anti-cd73 antibodies | |
| US20120010388A1 (en) | LeY SPECIFIC BIOTHERAPEUTIC | |
| EP4628508A1 (en) | Anti-ilt4 antibody as well as preparation method therefor and use thereof | |
| JP7329288B2 (ja) | 腫瘍細胞を死滅させるための医薬 |